Phenotype-Guided Vasoactive Management
Phase 3
Phenotype-Guided Vasoactive Management is one of 15 therapeutic programs targeting Kidney. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
19 competitors in Kidney
#DrugCompanyPhaseTrials
1Nulojix
Bristol-Myers SquibbApproved
Prevymis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Trimethoprim-Sulfamethoxazole
AstellasPhase 3
Fludara
SanofiPhase 1
Phenotype-Guided Vasoactive Management
JJennifer Cutler
Phase 3
Actemra
RochePreclinical
Imlifidase
HHansa Biopharma AB
Phase 2
Imuran
LLegacy Health System
Preclinical
Glucagon
XXeris Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company
- JJennifer Cutler